Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Strategies in Newly Diagnosed AL Amyloidosis
NCT06376214Phase 2Recruiting
- Sponsor
- Nanjing University School of Medicine
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in systemic light chain amyloidosis (3 arms), sponsored by Nanjing University School of Medicine. Primary endpoints: Hematological complete response rate at 6 months and Organ response rate at 1 year. Started Jan 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT06376214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376214.